October 6, 2016 08:57 AM EDT
R&D
Pharma

Te­va hands Cell­tri­on $160M to grab US rights on two biosim­i­lars of Roche block­busters

John Carroll

Editor & Founder

Te­va is ex­pand­ing its pipeline of biosim­i­lars. The Is­raeli phar­ma com­pa­ny agreed to hand over $160 mil­lion to part­ner with Ko­rea’s Cell­tri­on on copy­cat ver­sions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times